May. 16 at 12:50 PM
$AGEN &
$INKT
Amazing the PR dept does not work for Mink either.
MiNK Therapeutics (NASDAQ: INKT) reported its Q1 2025 financial results and clinical progress. The company achieved a significant breakthrough with a complete remission in testicular cancer using a single infusion of agenT-797. Clinical trials are advancing, including an active Phase 2 trial in gastric cancer at Memorial Sloan Kettering. The company presented promising data showing agenT-797's effectiveness in PD-1-resistant gastroesophageal cancers. MiNK is pursuing strategic partnerships in oncology, immunology, and engineered cell therapies. Financially, Q1 2025 ended with
$3.2 million cash, reduced cash burn to
$1.3 million (vs
$2.5M in Q1 2024), and a net loss of
$2.8 million (
$0.70 per share). The company expects NIAID funding for its GvHD program by June 2025.
https://www.stocktitan.net/news/INKT/